MedTrace Logo

Red Blood Cell Distributions (RDW, RDW-CW) and Lymphocyte Monocyte Ratios (LMR) for the Malignant Thyroid Nodules

NCT06283368 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 172

Last updated 2024-03-01

No results posted yet for this study

Summary

Thyroid surgery is the most common type of surgery among endocrine surgeries. This surgery is performed for patients with suspected malignancy, patients diagnosed with malignancy, and toxic nodular goiter. In addition to vocal cord injury, which is the most important complication of thyroid surgery, hypocalcemia due to hypoparathyroidism and surgical wound complications (such as hematoma, and fistula) can also be observed, and malignancy surgery increases the risk of recurrent laryngeal nerve injury. Therefore, it is important to differentiate these groups using non-invasive methods before surgery.

Tumor-related inflammation is activated as a result of bone marrow and inflammation induced by malignancies. Insufficiently controlled or uncontrolled inflammatory activity may be responsible for malignant transformation. Lymphocyte monocyte ratio and red blood cell distribution are parameters (RDW, RDW-CW) previously studied in terms of cancers.

Our aim in this study is to reveal the RDW, RDW-CW, and LMR calculated from complete blood count parameters in the preoperative period, as an indicator of malignant inflammatory response, in a non-invasive and inexpensive way before surgery or biopsy is performed to distinguish nodular goiter and thyroid malignancy.

Conditions

  • Thyroid Neoplasms Benign
  • Thyroid Nodule
  • Thyroid Cancer
  • Thyroid Diseases

Interventions

PROCEDURE

Thyroidectomy, Bilaterally Total

Thyroidectomy, Bilaterally Total

PROCEDURE

Thyroidectomy, Unilaterally Total

Thyroidectomy, Unilaterally Total

PROCEDURE

Thyroidectomy, Complementary

Thyroidectomy, Complementary

PROCEDURE

Thyroidectomy, Near Total

Thyroidectomy, Near Total

Sponsors & Collaborators

  • Kahramanmaras Sutcu Imam University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2021-01-31
Completion
2021-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06283368 on ClinicalTrials.gov